Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A B Spurdle

Showing results (21-30 of 42) with videos related to

Pageof 5
Sort By:
International Journal of Cancer|April 13, 2000
CYP17 promotor polymorphism and ovarian cancer riskA B Spurdle, X Chen, M Abbazadegan, et al.
Gynecologic Oncology|May 1, 2018
The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancerC M Nagle, E J Crosbie, A Brand, et al.
Human Mutation|October 8, 2005
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer familiesA A Tesoriero, E M Wong, M A Jenkins, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
Impact of weight change and weight cycling on risk of different subtypes of endometrial cancerC M Nagle, L Marquart, C J Bain, et al.
Breast Cancer Research : BCR|October 13, 2001
The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in AustraliaA Marsh, A B Spurdle, B C Turner, et al.
European Journal of Human Genetics : EJHG|January 1, 1996
Mutations in the human mannose-binding protein gene: frequencies in several population groupsR J Lipscombe, D W Beatty, M Ganczakowski, et al.
Genetics|March 1, 1997
The geographic distribution of human Y chromosome variationM F Hammer, A B Spurdle, T Karafet, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 26, 2001
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian womenA B Spurdle, J L Hopper, X Chen, et al.
Journal of the National Cancer Institute|October 19, 2000
CYP17 promoter polymorphism and breast cancer in Australian women under age forty yearsA B Spurdle, J L Hopper, G S Dite, et al.
ESMO Open|April 8, 2026
BRCA1 and BRCA2 pathogenic variants increase the risk of four less common cancer typesH Sasagawa, M Endo, Y Iwasaki, et al.
Pageof 5

Showing results (21-30 of 42) with videos related to

Sort By:
Pageof 5
International Journal of Cancer|April 13, 2000
CYP17 promotor polymorphism and ovarian cancer riskA B Spurdle, X Chen, M Abbazadegan, et al.
Gynecologic Oncology|May 1, 2018
The association between diabetes, comorbidities, body mass index and all-cause and cause-specific mortality among women with endometrial cancerC M Nagle, E J Crosbie, A Brand, et al.
Human Mutation|October 8, 2005
Molecular characterization and cancer risk associated with BRCA1 and BRCA2 splice site variants identified in multiple-case breast cancer familiesA A Tesoriero, E M Wong, M A Jenkins, et al.
European Journal of Cancer (Oxford, England : 1990)|April 16, 2013
Impact of weight change and weight cycling on risk of different subtypes of endometrial cancerC M Nagle, L Marquart, C J Bain, et al.
Breast Cancer Research : BCR|October 13, 2001
The intronic G13964C variant in p53 is not a high-risk mutation in familial breast cancer in AustraliaA Marsh, A B Spurdle, B C Turner, et al.
European Journal of Human Genetics : EJHG|January 1, 1996
Mutations in the human mannose-binding protein gene: frequencies in several population groupsR J Lipscombe, D W Beatty, M Ganczakowski, et al.
Genetics|March 1, 1997
The geographic distribution of human Y chromosome variationM F Hammer, A B Spurdle, T Karafet, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|December 26, 2001
The steroid 5alpha-reductase type II TA repeat polymorphism is not associated with risk of breast or ovarian cancer in Australian womenA B Spurdle, J L Hopper, X Chen, et al.
Journal of the National Cancer Institute|October 19, 2000
CYP17 promoter polymorphism and breast cancer in Australian women under age forty yearsA B Spurdle, J L Hopper, G S Dite, et al.
ESMO Open|April 8, 2026
BRCA1 and BRCA2 pathogenic variants increase the risk of four less common cancer typesH Sasagawa, M Endo, Y Iwasaki, et al.
Pageof 5